Business Context and Reporting Period
This Form 8-K Current Report was filed by Aytu BioScience, Inc. on June 12, 2020. The filing addresses the resolution of litigation related to the company's October 2019 acquisition of assets from Cerecor Inc. and associated stockholder proposals regarding the convertibility of preferred stock and warrants.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or operating margins. The only financial figures disclosed relate to transaction costs and settlement amounts:
- Acquisition Consideration: Approximately $32 million total (comprising $4.5 million cash, $12.5 million in Series G Preferred Stock, and $16.575 million in assumed liabilities).
- Litigation Settlement (Pliscott et al.): $125,000 paid to plaintiffs' counsel for attorneys' fees and expenses.
- Litigation Settlement (Franchi et al.): Amount agreed on June 9, 2020, is not specified in the text.
Material Changes
The primary material change reported is the final settlement of three purported stockholder class actions (Pliscott v. Disbrow, Kirschenbaum v. Aytu BioScience, Inc., and Sebree v. Disbrow) and a separate action (Franchi v. Aytu BioScience Inc.). These lawsuits alleged that directors breached fiduciary duties by failing to disclose material information regarding the Cerecor acquisition and related stockholder proposals. The company resolved these claims by including additional disclosures in a definitive proxy statement filed on December 23, 2019, and agreeing to pay legal fees.
Outlook, Risks, and Management Commentary
Management Commentary: Management stated that while they believed the initial disclosure in the preliminary proxy statement was sufficient, they opted to include minor additional disclosures to settle the plaintiffs' claims and avoid litigation costs. The company confirmed that the failure to obtain stockholder approval for the conversion of Series G Preferred Stock would not have unwound the Cerecor acquisition.
Risks and Contingencies: The filing notes that the Delaware Court of Chancery retained jurisdiction solely to adjudicate the application for attorneys' fees. The company has now settled the outstanding litigation related to the preliminary proxy statement.
Investor Verification Checklist
- Verify the exact dollar amount paid to settle the Franchi v. Aytu BioScience Inc. litigation, as the specific figure is not disclosed in this text.
- Confirm the status of the Series G Preferred Stock conversion and whether stockholder approval was ultimately granted.
- Review the definitive proxy statement filed on December 23, 2019, to understand the "minor additional disclosures" that mooted the plaintiffs' claims.
- Assess the impact of the $125,000 settlement and any additional legal fees on the company's current cash position.